Search results
Results from the Health.Zone Content Network
A maternal RSV vaccine, given during RSV season to people who are 32–36 weeks pregnant, can also protect babies once they are born. To offer protection to the baby, the mother must receive the ...
The National Vaccine Injury Compensation Program – which covers most vaccines -- allows people to file a petition if they believe they’ve been hurt by one. According to statistics from the ...
The vaccine should slow the spread of COVID-19 around the world. Fewer people should get sick, and more lives can be saved. The Pfizer, Moderna, and Novavax vaccines have been shown to be at least ...
A number of vaccines, especially live-virus vaccines, should not be given to pregnant women, because they may be harmful to the baby. (A live-virus vaccine is made using the live strains of a virus.)
In the next phase, people 65 to 74 and adults with underlying health conditions will be offered the vaccine. This will put many families in a situation where older adults are vaccinated, but their ...
Researchers found that when pregnant people received the Abrysvo vaccine during weeks 32–36 of pregnancy, it reduced their baby’s risk of lower respiratory tract disease from RSV by 34.7% ...
The FDA said to avoid the possibility, the vaccine should be given only between 32 weeks and 36 weeks of pregnancy, a few weeks later than during the clinical trial.
COVID-19 pandemic. The Access to COVID-19 Tools Accelerator (ACT Accelerator or ACT-A), or the Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines, is a G20 initiative announced by pro-tem Chair Mohammed al-Jadaan on 24 April 2020. [1]